Dr. Galambos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
95 Collier Rd NW
Ste 4085
Atlanta, GA 30309Phone+1 404-355-3200Fax+1 404-355-9819
Education & Training
- Emory University School of MedicineFellowship, Gastroenterology, 1987 - 1989
- University of WashingtonResidency, Internal Medicine, 1984 - 1987
- Emory University School of MedicineClass of 1984
Certifications & Licensure
- GA State Medical License 1987 - 2025
- WA State Medical License 1984 - 1985
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
- Top MD Consumers Checkbook
Clinical Trials
- Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Start of enrollment: 2014 Mar 27
- Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Start of enrollment: 2014 Apr 01
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease Start of enrollment: 2020 Jun 22
Publications & Presentations
PubMed
- 107 citationsSeladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, ra...David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael R Galambos
The Lancet. Gastroenterology & Hepatology. 2017-10-01 - 35 citationsA phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.Christopher L Bowlus, Michael R Galambos, Richard J Aspinall, Gideon M Hirschfield, David E J Jones
Journal of Hepatology. 2022-08-01 - 11 citationsOpen-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield
Alimentary Pharmacology & Therapeutics. 2024-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: